NCT03366688View on ClinicalTrials.gov

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

November 5, 2018

Study Completion Date

November 5, 2018

Conditions
Hypercholesterolemia
Interventions
DRUG

IBI306

Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

DRUG

placebo

Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03366688 - Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects. | Biotech Hunter | Biotech Hunter